1
|
Di Giacomo A, Mason P, Snijder R, Abdul-Ahad A, Lahn M, Van der Veen L, Hammett T, Zorrilla R, Pickering C, Durini M, Simonelli M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans T, Maio M. 119P Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
2
|
Bertoni F, Tarantelli C, Spriano F, Cascione L, Civanelli E, Cannas E, Mensah A, Arribas A, Napoli S, Rinaldi A, Stathis A, Niewola K, Di Conza G, Lahn M, Santoro A, Carlo-Stella C. 53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023] Open
|
3
|
Di Giacomo A, Santangelo F, Amato G, E. Simonetti, Graham J, Lahn M, van der Veen L, Hammett T, Pickering C, Durini M, Ziyang T, Lakshmikanth T, Brodin P, Occhipinti M, Simonelli M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans T, Maio M. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
4
|
Cavinato L, Gozzi N, Sollini M, Carlo-Stella C, Chiti A, Ieva F. Recurrence-specific supervised graph clustering for subtyping Hodgkin Lymphoma radiomic phenotypes. Annu Int Conf IEEE Eng Med Biol Soc 2021; 2021:2155-2158. [PMID: 34891715 DOI: 10.1109/embc46164.2021.9629625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The prediction at baseline of patients at high risk for therapy failure or recurrence would significantly impact on Hodgkin Lymphoma patients treatment, informing clinical practice. Current literature is extensively searching insights in radiomics, a promising framework for high-throughput imaging feature extraction, to derive biomarkers and quantitative prognostic factors from images. However, existing studies are limited by intrinsic radiomic limitations, high dimensionality among others. We propose an exhaustive patient representation and a recurrence-specific multi-view supervised clustering algorithm for estimating patient-to-patient similarity graph and learning recurrence probability. We stratified patients in two risk classes and characterize each group in terms of clinical variables.
Collapse
|
5
|
Moreno V, Brana I, Sepulveda Sanchez J, Vieito Villar M, Hernández-Guerrero T, Doger B, Saavedra O, Italiano A, Michot JM, Musuraca G, Asierto P, Carlo-Stella C, Sarmiento R, De Alvaro J, Di Martino J, Zuraek M, Sánchez Pérez T, Filvaroff E, Hanna B, Nikolova Z. Phase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz251.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Radford J, Kahl B, Hamadani M, Carlo-Stella C, O'Connor O, Ardeshna K, Feingold J, He S, Reid E, Solh M, Chung K, Heffner L, Ungar D, Caimi P. ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.60_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and The Christie NHS Foundation Trust; Manchester United Kingdom
| | - B. Kahl
- Department of Medicine; Oncology Division, Washington University in St. Louis; St. Louis MO United States
| | - M. Hamadani
- Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee WI United States
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Cancer Center, Humanitas University; Milan Italy
| | - O.A. O'Connor
- Center for Lymphoid Malignancies; NewYork-Presbyterian/Columbia University Irving Medical Center; New York United States
| | - K.M. Ardeshna
- Department of Haematology; University College London Hospitals NHS Foundation Trust; London United Kingdom
| | - J. Feingold
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - S. He
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - E. Reid
- Division of Hematology/Oncology; University of California San Diego Health Moores Cancer Center; La Jolla CA United States
| | - M. Solh
- Blood and Marrow Transplant Program; Northside Hospital; Atlanta GA United States
| | - K. Chung
- Department of Hematology and Oncology; Greenville Health System; Greenville SC United States
| | - L. Heffner
- Department of Haematology and Medical Oncology; Winship Cancer Institute, Emory University; Atlanta GA United States
| | - D. Ungar
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - P. Caimi
- University Hospitals Cleveland Medical Center; Case Western Reserve University (CWRU); Cleveland OH United States
| |
Collapse
|
7
|
Dickinson M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner F, Sureda A, Salles G, Martinez J, Crump M, Thomas D, Morcos P, Ferlini C, Broeske A, Bacac M, Dimier N, Umaña P, Moore T, Weisser M, Hutchings M. CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.59_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M.J. Dickinson
- Peter MacCallum Cancer Centre; Royal Melbourne Hospital, The University of Melbourne; East Melbourne Australia
| | - F. Morschhauser
- Department of Hematology; Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées; Lille France
| | - G. Iacoboni
- Department of Hematology; Vall d'Hebron Hospital; Barcelona Spain
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Humanitas University; Milan Italy
| | | | - A. Sureda
- Hematology Department; Institut Català d'Oncologia Hospitalet; Barcelona Spain
| | - G. Salles
- Service d'Hématologie Clinique, Université Claude Bernard de Lyon; Lyon University Hospital; Pierre-Bénite France
| | - J. Martinez
- Servicio de Hematología; Hospital 12 de Octubre; Madrid Spain
| | - M. Crump
- Medical Oncology & Haematology; Princess Margaret Hospital; Toronto Canada
| | - D.N. Thomas
- Roche Innovation Center New York; Roche Pharma Research and Early Development (pRED); New York City United States
| | - P.N. Morcos
- Roche Innovation Center New York; Roche Pharma Research and Early Development (pRED); New York City United States
| | - C. Ferlini
- Roche Innovation Center Basel; Roche Pharma Research and Early Development (pRED); Basel Switzerland
| | - A. Broeske
- Roche Innovation Center Munich; Roche Pharma Research and Early Development (pRED); Penzberg Germany
| | - M. Bacac
- Roche Innovation Center Zurich; Roche Pharma Research and Early Development (pRED); Schlieren Switzerland
| | - N.J. Dimier
- Roche Pharma; Roche Ltd; Welwyn United Kingdom
| | - P. Umaña
- Roche Innovation Center Zurich; Roche Pharma Research and Early Development (pRED); Schlieren Switzerland
| | - T. Moore
- Roche Innovation Center Basel; Roche Pharma Research and Early Development (pRED); Basel Switzerland
| | - M. Weisser
- Roche Innovation Center Munich; Roche Pharma Research and Early Development (pRED); Penzberg Germany
| | - M. Hutchings
- Department of Haematology and Phase 1 Unit; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark
| |
Collapse
|
8
|
Castagna L, Bramanti S, Devillier R, Pagliardini T, Sarina B, Lemarie C, Furst S, Mariotti J, Granata A, de Philippis C, Harbi S, Legrand F, Maisano V, Bouabdallah R, Carlo-Stella C, Calmels B, Chabannon C, Blaise D, Santoro A. IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). Hematol Oncol 2019. [DOI: 10.1002/hon.109_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Castagna
- Hematology; Humanitas Research Center; Rozzano Italy
| | - S. Bramanti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Sarina
- Hematology; Humanitas Research Center; Rozzano Italy
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - A. Granata
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - F. Legrand
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | | | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - A. Santoro
- Hematology; Humanitas Research Center; Rozzano Italy
| |
Collapse
|
9
|
de Philippis C, Legrande F, Bramanti S, Montes de Oca C, Dulery R, Bouabdallah R, Granada A, Devillier R, Mariotti J, Sarina B, Harbi S, Maisano V, Furst S, Pagliardini T, Weiller P, Lemarie C, Calmels B, Chabannon C, Carlo-Stella C, Santoro A, Mohty M, Blaise D, Castagna L. CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. Hematol Oncol 2019. [DOI: 10.1002/hon.107_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - F. Legrande
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Bramanti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | | | - R. Dulery
- Hematology; Hospital Saint-Antoine; Paris France
| | | | - A. Granada
- Hematology; Institut Paoli Calmettes; Marseille France
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - B. Sarina
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - P.J. Weiller
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - M. Mohty
- Hematology; Hospital Saint-Antoine; Paris France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - L. Castagna
- Hematology; Humanitas Cancer Center; Rozzano Italy
| |
Collapse
|
10
|
Mazza R, Spina M, Califano C, Gaudio F, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati A, Rodari M, Giordano L, Balzarotti M, Gallamini A, Ricardi U, Chauvie S, Merli F, Carlo-Stella C, Santoro A. DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.100_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Mazza
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - M. Spina
- Medical Oncology Division; Centro Riferimento Oncologico; Aviano Italy
| | - C. Califano
- Onco-Hematology Department; A. Tortora Hospital; Pagani Italy
| | - F. Gaudio
- Emergency and Transplantation Department; Hematology section, University of Bari; Bari Italy
| | - M. Carella
- Hematological Consultant; Casa di Cura La Madonnina; Milano Italy
| | - U. Consoli
- Garibaldi Nesima Hospital; Hematology Department; Catania Italy
| | - F. Palombi
- Hematology Department; Regina Elena National Cancer Institute; Roma Italy
| | - M. Musso
- Onco-Hematology Unit; Casa di Cura “La Maddalena”; Palermo Italy
| | - A. Pulsoni
- Cellular Biotechnologies and Hematology Department; Policlinico Umberto I, Sapienza University; Rome Italy
| | - S. Kovalchuk
- Hematology Department; AOU Carreggi; Firenze Italy
| | - M. Bonfichi
- Hematology Division; IRCCS Policlinico S. Matteo; Pavia Italy
| | - F. Ricci
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - A. Fabbri
- Hematology Unit; AOU Senese; Siena Italy
| | - A. Liberati
- Onco-Hematology Division; S. Maria Hospital; Terni Italy
| | - M. Rodari
- Humanitas Reserch Hospital; Nuclear Medicin Unit; Rozzano-Milano Italy
| | - L. Giordano
- Biostatistic Unit; Humanitas Research Hospital; Rozzano Milano Italy
| | - M. Balzarotti
- Medical Oncology and Hematology Department; Humanitas Research Hospital; Rozzano-Milano Italy
| | - A. Gallamini
- Research; Innovation and Statistc Depatment, Centre Antoine-Lacassagne; Nice France
| | - U. Ricardi
- Oncology Department; Radiation Oncology, University of Torino; Torino Italy
| | - S. Chauvie
- Medical Physics Department; S Croce e Carle Hospital; Cuneo Italy
| | - F. Merli
- Hematology Department; Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - C. Carlo-Stella
- Medical Oncology and Hematology Department; Humanitas University; Rozzano-Milano Italy
| | - A. Santoro
- Medical Oncology and Hematology Department; Humanitas University; Rozzano-Milano Italy
| |
Collapse
|
11
|
Abstract
A number of clonogenic assays for short-term bone marrow culture is now available for the quantitative analysis of the various hematopoietic progenitor cell classes. The short-term assays are not suitable to analyse either stem cell selfrenewal or interactions of hematopoietic progenitors with stromal cells, especially those requiring direct cell-to-cell or cell-to-matrix contact. The technique of longterm bone marrow culture (LTBMC) allows a sustained production of myeloid cells when marrow is placed in liquid culture at relatively high cell concentration, with appropriate supplements, temperature and feeding conditions. A peculiar feature of LTBMC is that the stromal cells promote selfrenewal as well as differentiation of the stem cells, without the need to add exogenous growth factors. The LTBMC system offers an approach able to investigate not only the proliferative and differentiative events but also sustained cell production and selfrenewal of any clonogenic cell types. In the last years, the technique of LTBMC has been increasingly used by several groups to investigate hematopoietic regulation, stromal cell function and the interactions among stromal and hematopoietic cells. In the present report, the biology of LTBMC and their possible clinical applications will be reviewed.
Collapse
Affiliation(s)
- C. Carlo-Stella
- Department of Hematology, Bone Marrow Transplantation Unit, University of Parma, Parma - Italy
| | - L. Mangoni
- Department of Hematology, Bone Marrow Transplantation Unit, University of Parma, Parma - Italy
| | - V. Rizzoli
- Department of Hematology, Bone Marrow Transplantation Unit, University of Parma, Parma - Italy
| |
Collapse
|
12
|
Carlo-Stella C, Barde P, Delarue R, Scarfò L, Viswanadha S, Locatelli S, Gandolfi S, Pittari V, Morello L, Magagnoli M, Pilipow K, De Paoli F, Lugli E, Santoro A, Ferreri A. SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI-CENTER STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_133] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. Carlo-Stella
- Department of Biomedical Sciences, Department of Oncology and Hematology; Humanitas University, Humanitas Clinical and Research Hospital; Milan Italy
| | - P. Barde
- Clinical Research; Rhizen Pharmaceuticals SA; La Chaux-de-Fonds Switzerland
| | - R. Delarue
- Department of Hematology; AP-HP Hopital universitaire Necker-Enfants malades; Paris France
| | - L. Scarfò
- Department of Hematology; Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele; Milan Italy
| | - S. Viswanadha
- Drug Discovery; Incozen Therapeutics Pvt Ltd; Hyderabad India
| | - S. Locatelli
- Department of Oncology and Hematology; Humanitas Research Hospital; Milan Italy
| | - S. Gandolfi
- Department of Oncology and Hematology; Humanitas Research Hospital; Milan Italy
| | - V. Pittari
- Department of Oncology and Hematology; Humanitas Research Hospital; Milan Italy
| | - L. Morello
- Department of Oncology and Hematology; Humanitas Research Hospital; Milan Italy
| | - M. Magagnoli
- Department of Oncology and Hematology; Humanitas Research Hospital; Milan Italy
| | - K. Pilipow
- Laboratory of Translational Immunology; Humanitas Clinical and Research Center; Milan Italy
| | - F. De Paoli
- Laboratory of Translational Immunology; Humanitas Clinical and Research Center; Milan Italy
| | - E. Lugli
- Laboratory of Translational Immunology; Humanitas Clinical and Research Center; Milan Italy
| | - A. Santoro
- Department of Biomedical Sciences, Department of Oncology and Hematology; Humanitas University, Humanitas Clinical and Research Hospital; Milan Italy
| | - A. Ferreri
- Unit of Lymphoid Malignancies; IRCCS San Raffaele Scientific Institute; Milan Italy
| |
Collapse
|
13
|
Bruscaggin A, Spina V, Di Trani M, Martini M, Locatelli S, Cupelli E, Forestieri G, Condoluci A, Cuccaro A, Moccia A, Stathis A, Manzoni M, Deambrogi C, Diop F, Stüssi G, Cavalli F, Bertoni F, Zucca E, Larocca L, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_51] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Bruscaggin
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Spina
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - M. Di Trani
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - M. Martini
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - S. Locatelli
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - E. Cupelli
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Forestieri
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - A. Condoluci
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Cuccaro
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - A. Moccia
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Manzoni
- Department of Oncology and Hemato-Oncology; University of Milano; Milan Italy
| | - C. Deambrogi
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - F. Diop
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Stüssi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - E. Zucca
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L.M. Larocca
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - S. Hohaus
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - C. Carlo-Stella
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - D. Rossi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
14
|
Morello L, Rattotti S, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly T, Di Rocco A, Carli G, Defrancesco I, Giordano L, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Morello
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - S. Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - T. van Meerten
- Department of Hematology; University Medical Center Groningen; Groningen The Netherlands
| | - K. Krawczyk
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - F. Moita
- Instituto Português de Oncologia de Lisboa, Francisco Gentil; Lisbon Portugal
| | - D. Marino
- Oncology Unit 1; Veneto Institute of Oncology IOV-IRCCS; Padova Italy
| | - S. Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences; University of Torino; Torino Italy
| | - M. Szymczyk
- Department of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology; Warsaw Poland
| | - I. Aurer
- Division of Hematology, Department of Internal Medicine; University Hospital Centre Zagreb; Zagreb Croatia
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G. Carli
- Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza Italy
| | - I. Defrancesco
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - L. Giordano
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital Munich; Munchen Germany
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - L. Arcaini
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| |
Collapse
|
15
|
Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D. Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:1644-1646. [PMID: 27748737 DOI: 10.1038/bmt.2016.257] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- L Castagna
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - B Sarina
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Crocchiolo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Bramanti
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Furst
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Devillier
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Coso
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Bouabdallah
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Mokart
- Intensive Care Unit, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Harbi
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - L Giordano
- Biostatistical Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - A Rimondo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - P Jean Weiller
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - C Carlo-Stella
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - A Santoro
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Humanitas University, Rozzano, Italy
| | - C Chabannon
- Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - D Blaise
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| |
Collapse
|
16
|
Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, Carlo-Stella C. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia 2016; 30:2402-2405. [PMID: 27499137 DOI: 10.1038/leu.2016.224] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- S L Locatelli
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - G Careddu
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - G Inghirami
- Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.,Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.,Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA
| | - L Castagna
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | | | - A Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Humanitas University, Rozzano, Italy
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| |
Collapse
|
17
|
Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D. The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant 2016; 51:1134-6. [DOI: 10.1038/bmt.2016.69] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
18
|
Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015; 17:242-9. [PMID: 25648539 PMCID: PMC7169814 DOI: 10.1111/tid.12365] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 11/24/2014] [Accepted: 01/18/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND Recently, a platform of T-cell replete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using post-transplant cyclophosphamide (Cy) has shown high reproducibility and acceptable safety profile. METHOD This prospective cohort analysis allowed us to collect data on infections among 70 consecutive recipients of haplo-HSCT affected by various hematologic malignancies. RESULTS After a median follow-up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59-81) at 100 days and 77% (95% CI 67-87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus-virus-associated cystitis was 19% (13/70). Cumulative incidence of bacterial and fungal infections at 1 year were 63% (95% CI 51-75) and 12% (95% CI 4-19), respectively. Of note, only 1 invasive fungal infection occurred beyond 1 year after transplant (day +739). CONCLUSION In conclusion, despite a high rate of viral infections in the early period, present data suggest a satisfactory infectious profile after T-cell replete haplo-HSCT using post-transplant Cy. These results may help clinicians to improve both prophylactic and therapeutic antimicrobial strategies in this emerging haploidentical setting.
Collapse
Affiliation(s)
- R Crocchiolo
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Cheikh JE, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. Bone Marrow Transplant 2015; 51:462-5. [PMID: 26595078 DOI: 10.1038/bmt.2015.289] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L Castagna
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Furst
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | | | - J El Cheikh
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - A Granata
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - E Mauro
- Department of Hematology, Ospedale Ferrarotto, Catania, Italy
| | - C Faucher
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - B Mohty
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - S Harbi
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - R Devillier
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Cell Therapy Unit Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| |
Collapse
|
20
|
Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L, Blaise D. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant 2015; 51:194-8. [PMID: 26551778 DOI: 10.1038/bmt.2015.270] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 09/24/2015] [Accepted: 09/29/2015] [Indexed: 11/12/2022]
Abstract
Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases lacking HLA-identical donor. Although it provides low incidences of GVHD, the efficacy of Haplo-SCT is still questioned, especially for patients with myeloid malignancies. Thus, we analyzed 60 consecutive patients with refractory (n=30) or high-risk CR (n=30) AML or myelodysplastic syndromes (MDSs) who underwent PT-Cy Haplo-SCT. The median age was 57 years (22-73 years), hematopoietic cell transplantation comorbidity index was ⩾3 in 38 patients (63%) and Haplo-SCT was the second allogeneic transplantation for 10 patients (17%). Although most of patients received PBSC as graft source (n=48, 80%), we found low incidences of grade 3-4 acute (2%) and severe chronic GVHD (4%). Among patients with high-risk CR diseases, 1-year non-relapse mortality, cumulative incidence of relapse, progression-free and overall survivals were 20%, 32%, 47% and 62%, respectively. In patients with refractory disease, corresponding results were 34%, 35%, 32% and 37%, respectively. We conclude that PT-Cy Haplo-SCT could provide promising anti-leukemic effect even in the setting of very advanced diseases. Thus, it represents a viable alternative for high-risk AML/MDS patients without HLA-identical donor.
Collapse
Affiliation(s)
- R Devillier
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Fürst
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - J El-Cheikh
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - A Granata
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Aix-Marseille University, Medicine Faculty, Marseille, France.,Cell Therapy Facility, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Harbi
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Faucher
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - P-J Weiller
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - N Vey
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| |
Collapse
|
21
|
Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant 2015; 50:499-504. [PMID: 25621797 DOI: 10.1038/bmt.2014.304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 10/27/2014] [Accepted: 10/31/2014] [Indexed: 11/09/2022]
Abstract
Persistence of disease after salvage therapy among relapsed or refractory Hodgkin lymphoma (HL) patients predicts poor outcome. Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Disease response was based on 18-fluoro-deoxyglucose-positron emission tomography results in all patients. Overall response rate after HD-PAM was 78% and it did not differ among PR or stable/progressive disease patients (P=1.00). Response was associated with better OS: hazard ratio=0.32 (95% confidence interval: 0.13-0.77, P=0.01) irrespective of disease status before HD-PAM. Thirty-three patients (80%) were able to complete the planned treatment, intended as tandem autologous or auto-allo transplant. Hematological and extrahematological toxicity of HD-PAM was manageable, without any treatment-related death. In conclusion, HD-PAM is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% overall response rate and 80% rate of proceeding to further transplantation. The present data may be integrated with the growing literature on new drugs in the field of relapsed/refractory HL.
Collapse
Affiliation(s)
- L Castagna
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - R Crocchiolo
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Bramanti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - B Sarina
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Chiti
- Nuclear Medicine Department, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Mauro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Gandolfi
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Todisco
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Balzarotti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Anastasia
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Magagnoli
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Brusamolino
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| |
Collapse
|
22
|
Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol 2015; 26:167-172. [PMID: 25344361 DOI: 10.1093/annonc/mdu485] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In the late 1990s, the use of high-dose chemotherapy (HDCT) and stem-cell rescue held promise for patients with advanced and poor prognosis germ-cell tumors (GCT). We started a randomized phase II trial to assess the efficacy of sequential HDCT compared with cisplatin, etoposide, and bleomycin (PEB). PATIENTS AND METHODS Patients were randomly assigned to receive four cycles of PEB every 3 weeks or two cycles of PEB followed by a high-dose sequence (HDS) comprising HD-cyclophosphamide (7.0 g/m(2)), 2 courses of cisplatin and HD-etoposide (2.4 g/m(2)) with stem-cell support, and a single course of HD-carboplatin [area under the curve (AUC) 27 mg/ml × min] with autologous stem-cell transplant. Postchemotherapy surgery was planned on responding residual disease in both arms. The primary end point was progression-free survival (PFS). The study was designed to detect a 30% improvement of 5-year PFS (from 40% to 70%), with 80% power and two-sided α at 5%. RESULTS From December 1996 to March 2007, 85 patients were randomized: 43 in PEB and 42 in HDS arm. Median follow-up was 114.2 months [interquartile range (IQR): 87.7-165.8]. Complete or partial response with normal markers (PRm-) were obtained in 28 (65.1%) and 29 (69.1%) patients, respectively. Five-year PFS was 55.8% [95% confidence interval (CI) 42.8-72.8] and 54.8% (95% CI 41.6%-72.1%) in PEB and HDS arm, respectively (log-rank test P = 0.726). Five-year overall survival was 62.8% (95% CI 49.9-79.0) and 59.3% (95% CI 46.1-76.3). One toxic death (PEB arm) was recorded. CONCLUSIONS The study failed to meet the primary end point. Furthermore, survival estimates of conventional-dose chemotherapy higher than expected should be accounted for and will likely limit further improvements in the first-line setting. CLINICALTRIALS.GOV: NCT02161692.
Collapse
Affiliation(s)
| | - L Mariani
- Clinical Epidemiology and Trials Organization Unit
| | | | - S Lo Vullo
- Clinical Epidemiology and Trials Organization Unit
| | - N Nicolai
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | | | - D Raggi
- Department of Medical Oncology
| | - E Farè
- Department of Medical Oncology
| | - M Magni
- Department of Medical Oncology
| | - L Piva
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | | | - M Catanzaro
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - D Biasoni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - T Torelli
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Stagni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - C Bengala
- Department of Medical Oncology, Ospedale Misericordia, Grosseto
| | - C Barone
- Department of Medical Oncology, Oncologia Medica ASL TO5 Ospedale di Carmagnola, Turin
| | - I Schiavetto
- Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan
| | - S Siena
- Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano; Department of Medical Biotechnology and Translational Medicine
| | - G Pizzocaro
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - R Salvioni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - A M Gianni
- Department of Medical Oncology; Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy
| |
Collapse
|
23
|
Roberto A, Castagna L, Gandolfi S, Zanon V, Bramanti S, Sarina B, Crocchiolo R, Todisco E, Carlo-Stella C, Tentorio P, Timofeeva I, Santoro A, Della Bella S, Roederer M, Mavilio D, Lugli E. B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. Bone Marrow Transplant 2014; 50:317-9. [PMID: 25419693 DOI: 10.1038/bmt.2014.266] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- A Roberto
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - L Castagna
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Gandolfi
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - V Zanon
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Bramanti
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - B Sarina
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Crocchiolo
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - E Todisco
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - C Carlo-Stella
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - P Tentorio
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| | - I Timofeeva
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - A Santoro
- Hematology and Bone Marrow Transplant Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Della Bella
- 1] Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy [2] Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - M Roederer
- ImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - D Mavilio
- 1] Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy [2] Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - E Lugli
- Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy
| |
Collapse
|
24
|
Simonelli M, Zucali P, Suter M, Rubino L, Santoro A, Carlo-Stella C. 542 Tivantinib in combination with gemcitabine shows strong antitumor activity on mesothelioma cell lines and cytoskeletal effects via inhibition of actin. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70668-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis 2014; 5:e1434. [PMID: 25275595 PMCID: PMC4649516 DOI: 10.1038/cddis.2014.410] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 08/11/2014] [Accepted: 08/18/2014] [Indexed: 12/11/2022]
Abstract
Improving treatment of advanced melanoma may require the development of effective strategies to overcome resistance to different anti-tumor agents and to counteract relevant pro-tumoral mechanisms in the microenvironment. Here we provide preclinical evidence that these goals can be achieved in most melanomas, by co-targeting of oncogenic and death receptor pathways, and independently of their BRAF, NRAS, p53 and PTEN status. In 49 melanoma cell lines, we found independent susceptibility profiles for response to the MEK1/2 inhibitor AZD6244, the PI3K/mTOR inhibitor BEZ235 and the death receptor ligand TRAIL, supporting the rationale for their association. Drug interaction analysis indicated that a strong synergistic anti-tumor activity could be achieved by the three agents and the AZD6244–TRAIL association on 20/21 melanomas, including cell lines resistant to the inhibitors or to TRAIL. Mechanistically, synergy was explained by enhanced induction of caspase-dependent apoptosis, mitochondrial depolarization and modulation of key regulators of extrinsic and intrinsic cell death pathways, including c-FLIP, BIM, BAX, clusterin, Mcl-1 and several IAP family members. Moreover, silencing experiments confirmed the central role of Apollon downmodulation in promoting the apoptotic response of melanoma cells to the combinatorial treatments. In SCID mice, the AZD6244–TRAIL association induced significant growth inhibition of a tumor resistant to TRAIL and poorly responsive to AZD6244, with no detectable adverse events on body weight and tissue histology. Reduction in tumor volume was associated not only with promotion of tumor apoptosis but also with suppression of the pro-angiogenic molecules HIF1α, VEGFα, IL-8 and TGFβ1 and with inhibition of tumor angiogenesis. These results suggest that synergistic co-targeting of oncogenic and death receptor pathways can not only overcome melanoma resistance to different anti-tumor agents in vitro but can also promote pro-apoptotic effects and inhibition of tumor angiogenesis in vivo.
Collapse
Affiliation(s)
- G Grazia
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - C Vegetti
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - F Benigni
- San Raffaele Scientific Institute, URI, Milan, Italy
| | - I Penna
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - V Perotti
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - E Tassi
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - I Bersani
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - G Nicolini
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - S Canevari
- Functional Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - C Carlo-Stella
- 1] Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - A M Gianni
- Medical Oncology Unit 2, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - R Mortarini
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| | - A Anichini
- Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Medical Oncology, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
26
|
Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia 2014; 28:1861-71. [PMID: 24561519 DOI: 10.1038/leu.2014.81] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 02/07/2014] [Accepted: 02/13/2014] [Indexed: 01/07/2023]
Abstract
Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options. Interactions between the histone deacetylase inhibitor Givinostat and the RAF/MEK/ERK inhibitor Sorafenib were examined in HDLM-2 and L-540 HL cell lines. Exposure to Givinostat/Sorafenib induced a synergistic inhibition of cell growth (range, 70-80%) and a marked increase in cell death (up to 96%) due to increased H3 and H4 acetylation and strong mitochondrial injury. Gene expression profiling indicated that the synergistic effects of Givinostat/Sorafenib treatment are associated with the modulation of cell cycle and cell death pathways. Exposure to Givinostat/Sorafenib resulted in sustained production of reactive oxygen species (ROS) and activation of necroptotic cell death. The necroptosis inhibitor Necrostatin-1 prevented Givinostat/Sorafenib-induced ROS production, mitochondrial injury, activation of BH3-only protein BIM and cell death. Knockdown experiments identified BIM as a key signaling molecule that mediates Givinostat/Sorafenib-induced oxidative death of HL cells. Furthermore, in vivo xenograft studies demonstrated a 50% reduction in tumor burden (P<0.0001), a 5- to 15-fold increase in BIM expression (P < 0.0001) and a fourfold increase in tumor necrosis in Givinostat/Sorafenib-treated animals compared with mice that received single agents. These results provide a rationale for exploring Givinostat/Sorafenib combination in relapsed/refractory HL.
Collapse
Affiliation(s)
- S L Locatelli
- 1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - L Cleris
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - G G Stirparo
- 1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - S Tartari
- Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy
| | - E Saba
- Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy
| | - M Pierdominici
- Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
| | - W Malorni
- 1] Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Rome, Italy [2] Istituto San Raffaele Sulmona, Sulmona, Italy
| | - A Carbone
- Pathology Department, CRO Aviano, Aviano, Italy
| | - A Anichini
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - C Carlo-Stella
- 1] Department of Oncology and Hematology, Humanitas Cancer Center - Humanitas Clinical and Research Center, Milano, Italy [2] Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| |
Collapse
|
27
|
Magni M, Nicola MD, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant 2014; 49:485-91. [DOI: 10.1038/bmt.2013.214] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Revised: 11/19/2013] [Accepted: 11/19/2013] [Indexed: 11/09/2022]
|
28
|
Marconi M, Ascione B, Ciarlo L, Vona R, Garofalo T, Sorice M, Gianni AM, Locatelli SL, Carlo-Stella C, Malorni W, Matarrese P. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. Cell Death Dis 2013; 4:e863. [PMID: 24136227 PMCID: PMC3920963 DOI: 10.1038/cddis.2013.389] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 09/03/2013] [Accepted: 09/09/2013] [Indexed: 01/20/2023]
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) acts as an apoptosis inducer for cancer cells sparing non-tumor cell targets. However, several phase I/II clinical trials have shown limited benefits of this molecule. In the present work, we investigated whether cell susceptibility to TRAIL ligation could be due to the presence of TRAIL death receptors (DRs) 4 and 5 in membrane microdomains called lipid rafts. We performed a series of analyses, either by biochemical methods or fluorescence resonance energy transfer (FRET) technique, on normal cells (i.e. lymphocytes, fibroblasts, endothelial cells), on a panel of human cancer B-cell lines as well as on CD19+ lymphocytes from patients with B-chronic lymphocytic leukemia, treated with different TRAIL ligands, that is, recombinant soluble TRAIL, specific agonistic antibodies to DR4 and DR5, or CD34+ TRAIL-armed cells. Irrespective to the expression levels of DRs, a molecular interaction between ganglioside GM3, abundant in lymphoid cells, and DR4 was detected. This association was negligible in all non-transformed cells and was strictly related to TRAIL susceptibility of cancer cells. Interestingly, lipid raft disruptor methyl-beta-cyclodextrin abrogated this susceptibility, whereas the chemotherapic drug perifosine, which induced the recruitment of TRAIL into lipid microdomains, improved TRAIL-induced apoptosis. Accordingly, in ex vivo samples from patients with B-chronic lymphocytic leukemia, the constitutive embedding of DR4 in lipid microdomains was associated per se with cell death susceptibility, whereas its exclusion was associated with TRAIL resistance. These results provide a key mechanism for TRAIL sensitivity in B-cell malignances: the association, within lipid microdomains, of DR4 but not DR5, with a specific ganglioside, that is the monosialoganglioside GM3. On these bases we suggest that lipid microdomains could exert a catalytic role for DR4-mediated cell death and that an ex vivo quantitative FRET analysis could be predictive of cancer cell sensitivity to TRAIL.
Collapse
Affiliation(s)
- M Marconi
- Department of Theraputic Research and Medicine Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zambetti M, Guidetti A, Carlo-Stella C, De Benedictis E, Tessari A, Balzarini A, Caraceni A, Gianni L, Gianni AM. Abstract P2-12-08: Sorafenib for treatment of breast-cancer related lymphedema. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-12-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND Lymphedema (LE) is a common complication of breast cancer (BC) treatments conditioning disability that affects quality of life. Decongestive therapy is the most popular treatment but it determines only a transient advantage, while pharmacologic therapy didn't impact on LE. On the basis of clinical observations of LE regression in patients treated with sorafenib with antitumoral intent, we hypothesized that sorafenib could have an anti-LE activity through inhibition of vascular permeability by suppressing VEGFRs.
METHODS We conducted a single-arm, monoistitutional phase II study in BC patients with treatment-acquired LE of the arm. Major or uncontrolled cardiological disease, brain metastasis, history of thromboembolism were exclusion criteria. Concomitant chemo or hormonal therapy was allowed. Pts received sorafenib 200 mg daily for a maximum of 8 weeks. The primary end-point was to evaluate the efficacy of sorafenib as reduction of LE, defined by the percentage reduction (PR) of the difference between the total arm circumference (measured as the sum of the circumference at 12 points) of the affected and the controlateral arm (Starritt, Peterk JA Cancer 2001–10): [(Initial Difference – Final Difference)/Initial Difference] × 100.
Secondary end-points were safety and duration of response (DOR). The study was designed to test the null hypothesis that the PR of edema observed with this therapy was at most 20% versus the alternative hypothesis that the PR obtained by this regimen was ≥40%.
RESULTS From May 2009 to April 2011, 36 BC pts were enrolled. All pts underwent axillary dissection and 29 pts had received adjuvant radiotherapy, but none on the axilla. Median time from primary breast surgery and from occurrence of edema to study enrollement was 65 and 49 months, respectively. All pts are evaluable for efficacy and toxicity. Most common toxicities included grade 1–2 gastralgia (17%), hypertension (17%) and rash (43%); one patient experienced grade 3 hand-foot syndrome. Twenty-five pts completed the planned 8 weeks of therapy, 11 (31%) had early treatment discontinuation after 2 (n = 6), 4 (n = 4) and 6 (n = 1) weeks of treatment due to recurrent grade 2 toxicity or to relapse of disease (n = 1). The median PR of the difference between the two arms was 34% (range, 2–100), 14 pts (39%) experienced a LE reduction ≥40%. Among 25 pts who completed therapy, 12 (48%) achieved a PR ≥40%. The median difference of total circumferences between the LE and controlateral arm was significantly reduced after treatment: 37 cm (range 8–88) vs 25 cm (range 1–62) (p = 0.006). Best response was achieved after a median of 5 weeks of therapy (range 1– 6) and the median DOR was 8 weeks (range 4–15). Reduction of LE was associated with improvement of related symptoms. After discontinuation of study drug 84% pts presented a progressive increase of total circumference of LE arm and returned to values similar to baseline after a median of 7 weeks (range 2–11).
CONCLUSIONS: Low dose of sorafenib has a good toxicity profile and exerts a significant anti-LE activity in BC patients. The early but transient effect observed in this study suggests exploring different schedule of administration. Further studies are warranted in order to obtain a durable benefit in term of reduction of LE and quality of life.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-12-08.
Collapse
Affiliation(s)
- M Zambetti
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - A Guidetti
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - C Carlo-Stella
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - E De Benedictis
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - A Tessari
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - A Balzarini
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - A Caraceni
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - L Gianni
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| | - AM Gianni
- IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
| |
Collapse
|
30
|
Pennati M, Sbarra S, De Cesare M, Locatelli S, Carlo-Stella C, Zaffaroni N. 75 YM155-mediated Inhibition of Survivin Expression Enhances TRAIL-induced Apoptosis in Human Triple-negative Breast Cancer Cells. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71873-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Giacomini A, Lavazza C, Grazia G, Locatelli S, Cleris L, Righi M, Gianni A, Carlo-Stella C. 960 Combining Vascular Disruption Activity of TRAIL-expressing CD34+ Cells With Antiangiogenic Activity of Sorafenib Improves Regression of Tumor Growth. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71579-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Devizzi L, Guidetti A, Carlo-Stella C, Tarella C, Seregni E, Magni M, Di Nicola MA, Schiavello E, Matteucci P, Viviani S, Bombardieri E, Gianni AM. Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Guidetti A, Carlo-Stella C, Viviani S, Devizzi L, Locatelli S, Matteucci P, Marchianò A, Lanocita R, Magni M, Dodero A, Tarella C, Di Nicola MA, Corradini P, Gianni AM. Safety and activity of the multikinase inhibitor sorafenib in heavily pretreated patients with refractory/relapsed malignant lymphomas: Final results of a phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Zappasodi R, Pupa S, Bongarzone I, Ghedini GC, Castagnoli L, Miccichè F, Cabras A, Carlo-Stella C, Gianni AM, Di Nicola MA. Identification of HSP105 as a novel B-cell non-Hodgkin lymphoma (NHL) antigen (ag). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Carlo-Stella C, Guidetti A, Viviani S, Bonfante V, Marchiano A, Gatti B, D'Urzo C, Di Nicola MA, Corradini P, Gianni AM. Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2009; 36:1745-57. [PMID: 19455328 DOI: 10.1007/s00259-009-1141-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2008] [Accepted: 04/02/2009] [Indexed: 12/25/2022]
Abstract
PURPOSE The aim of this study was to carry out two different dose estimation approaches in patients with non-Hodgkin's lymphoma (NHL) treated with a myeloablative amount of (90)Y-labelled ibritumomab tiuxetan (Zevalin(R)) in an open-label dose escalation study. METHODS Twenty-seven patients with relapsed/refractory or de novo high-risk NHL receiving one myeloablative dose of (90)Y-ibritumomab tiuxetan followed by tandem stem cell reinfusion were evaluated for dose estimate. The injected activity was 30 MBq/kg in 12 patients and 45 MBq/kg in 15 patients. Dose estimation was performed 1 week prior to (90)Y-ibritumomab tiuxetan by injection of (111)In-ibritumomab tiuxetan (median activity: 200 MBq). The absorbed dose (D) and the biologically effective dose (BED) were calculated. RESULTS The absorbed doses per unit activity (Gy/GBq) were [median (range)]: heart wall 4.6 (2.5-9.7), kidneys 5.1 (2.8-10.5), liver 6.1 (3.9-10.4), lungs 2.9 (1.5-6.8), red marrow 1.0 (0.5-1.7), spleen 7.0 (1.5-14.4) and testes 4.9 (2.9-16.7). The absorbed dose (Gy) for the 15 patients treated with 45 MBq/kg were: heart wall 17.0 (8.7-25.4), kidneys 17.1 (7.9-22.4), liver 20.8 (15.4-28.3), lungs 8.1 (5.4-11.4), red marrow 3.1 (2.0-4.0), spleen 26.2 (17.0-35.6) and testes 17.3 (9.0-28.4). At the highest activities the acute haematological toxicity was mild or moderate and of very short duration, and it was independent of the red marrow absorbed dose. No secondary malignancy or treatment-related myelodysplastic syndrome was observed. No non-haematological toxicity (liver, kidney, lung) was observed during a follow-up period of 24-48 months. CONCLUSION The use of 45 MBq/kg of (90)Y-ibritumomab tiuxetan in association with stem cell autografting resulted in patients being free of toxicity in non-haematological organs. These clinical findings were in complete agreement with our dose estimations, considering both organ doses and BED values.
Collapse
Affiliation(s)
- C Chiesa
- Nuclear Medicine Division, Foundation IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Di Nicola MA, Carlo-Stella C, Zappasodi R, Passoni L, Liliana D, Magni M, Matteucci P, Mortarini R, Anichini A, Gianni AM. Immunization of indolent non-Hodgkin’s lymphoma patients with autologous monocyte-derived dendritic cells loaded with heat shocked and killed autologous tumor cells: A phase I study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3006 Background: To evaluate the safety and tolerability of vaccination with DCs loaded with killed tumor cells, 18 patients with measurable relapse/refractory follicular (12) and lymphoplasmocytoid (6) lymphoma have been enrolled in a phase I study. Methods: Each patient received at 2-weekly intervals 4 SC injections of 50x10e6 tumor-loaded DCs. Immature DCs were generated by 5-days culture of autologous monocytes in the presence of IL-4 and GM-CSF. Autologous CD19+ tumor cells, harvested from lymph nodes (12) and/or peripheral blood (6), were heat shocked and then irradiated by UVC. DCs were loaded for 48 hrs with killed tumor cells and then were cultured for 12 hrs in the presence of TNF-a. Median prior number of treatment regimens was 2 (range 1–5) comprising 4 patients treated with high-dose chemotherapy. The vaccination was started at least 6-months after the last chemotherapy treatment. Results: All patients were evaluable for toxicity and for efficacy with a median follow-up of 30.5 months (range 18–45 months). Overall, vaccinations were well tolerated and no autoimmune reactions were observed. Mild erythema in the site of injection developed in the majority of patients (12/18), but only in 2 cases induration and extended erythema was observed. Six of 18 patients had objective responses. Three patients had partial responses (PR). One is still in PR and the others have a PR lasting 7 and 15 months, respectively. Three patients had complete remission (CR) and are are still in CR with a mean CR duration of 17 months. The remaining 12 patients had stable disease (8) or progressive disease (4). In the patients in PR, a significant increase of anti autologous tumor-specific T cells, evaluated by ELISPOT assay for IFN-γ, was observed in the post-vaccination lymph nodes, compared to the tissue sample taken before vaccination. In addition, in the responding patients a significant reduction in peripheral blood of FoxP3+ regulatory T cells was observed. Conclusion: The injection of DCs loaded with killed tumor cells is a well-tolerated procedure achieving clinical and immunological responses also in the presence of significant tumor burden. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | | | | | - M. Magni
- Insituto Nazionale Tumori, Milan, Italy
| | | | | | | | | |
Collapse
|
38
|
Di Nicola MA, Carlo-Stella C, Mortarini R, Anichini A, Gianni AM. Ex-vivo culture with γchain cytokines restores defective maturation and activation of tumor infiltrating lymphocytes in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Ricca I, Compagno M, Ladetto M, Rocci A, Dell'Aquila M, Omedè P, De Marco F, D'Antico S, Caracciolo D, Ferrero D, Carlo-Stella C, Tarella C. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia 2005; 19:644-51. [PMID: 15716989 DOI: 10.1038/sj.leu.2403652] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The purpose of the study was to compare telomere length (TL) in peripheral blood progenitor cells (PBPC) collected after two tightly spaced high-dose (hd) chemotherapy courses. We assessed 37 previously untreated lymphoma patients undergoing a hd-chemotherapy program with autografting. They sequentially received hd-cyclophosphamide (CY) and hd-Ara-C, both followed by PBPC harvesting. Both post-CY and post-Ara-C harvests were assessed for TL by Southern blot analysis. In 12 patients, the assay was also performed on purified CD34+ cells. All patients displayed high PBPC mobilization following both hd-CY and hd-Ara-C. In all but one patient, TL was shorter in PBPC collected after Ara-C compared to CY: 7226bp (range: 4135-9852) vs 8282 bp (range 4895-14860) (P < 0.0001). This result was confirmed on CD34+ cells. Platelet recovery in patients receiving post-Ara-C PBPC was significantly slower compared to those receiving post-CY PBPC. In conclusion, (i) administration of tightly spaced hd-chemotherapy courses induces marked telomere shortening on harvested PBPC; (ii) engraftment kinetics seem slower, with delayed platelet recovery, in patients autografted with PBPC suffering marked TL erosion; (iii) long-term follow-up is required to verify whether PBPC with shortened telomeres display defective engraftment stability and/or risk of secondary leukemia; (iv) TL evaluation is advisable whenever new mobilization procedures are developed.
Collapse
MESH Headings
- Adolescent
- Adult
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/adverse effects
- Antigens, CD34/metabolism
- Antimetabolites, Antineoplastic/administration & dosage
- Antimetabolites, Antineoplastic/adverse effects
- Antineoplastic Agents, Alkylating/administration & dosage
- Antineoplastic Agents, Alkylating/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Combined Modality Therapy
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/adverse effects
- Cytarabine/administration & dosage
- Cytarabine/adverse effects
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Female
- Granulocyte Colony-Stimulating Factor/administration & dosage
- Granulocyte Colony-Stimulating Factor/adverse effects
- Hematopoietic Stem Cell Mobilization
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cells/metabolism
- Hematopoietic Stem Cells/pathology
- Humans
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/pathology
- Male
- Middle Aged
- Platelet Count
- Predictive Value of Tests
- Prednisone/administration & dosage
- Prednisone/adverse effects
- Telomere
- Transplantation, Autologous
- Vincristine/administration & dosage
- Vincristine/adverse effects
Collapse
Affiliation(s)
- I Ricca
- Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino and A. O. S. Giovanni Battista, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Anichini A, Mortarini R, Baldassari P, Carlo-Stella C, Guidetti A, Morelli D, Gianni AM, Parmiani G, Di Nicola D. 9 A phase I study of immunization with dendritic cells transduced with a vaccinia vector encoding the human tyrosinase gene in patients with metastatic melanoma. Melanoma Res 2004. [DOI: 10.1097/00008390-200408000-00025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, Bonati A. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 2003; 17:1783-93. [PMID: 12970778 DOI: 10.1038/sj.leu.2403032] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
MAP kinase/ERK kinase (MEK)-extracellular signal-regulated kinase (ERK) kinases are frequently activated in acute myelogenous leukemia (AML), and can have prosurvival function. The purpose of this study was to induce downmodulation of MEK-ERK activation in AML primary blasts in order to detect the effect on cell cycle progression and on the apoptosis of leukemic cells. We investigated 14 cases of AML with high ERK 1/2 activity and four cases with undetectable or very low activity. After 24 h incubation of the AML blasts with high ERK activity using PD98059 (New England BioLabs, Beverly, MA, USA), a selective inhibitor of MEK1 phosphorylation, at concentrations of 20 and 40 microM, we observed a strong decrease in the levels of ERK1/2 activity. A significant decrease of blast cell proliferation compared with untreated controls was found. In contrast, the proliferation of blast cells that expressed low or undetectable levels of ERK activity was not inhibited. Time-course analysis demonstrated that the downmodulation of MEK1/2, ERK1 and ERK2 dual-phosphorylation was evident even after 3 h of treatment with 20 and 40 microM. The cleavage of poly(ADP-ribose) polymerase (PARP), an early sign of apoptosis, appeared after 18 h of PD98059 treatment at concentrations of 20 and 40 microM in eight of the 14 cases. After 24 h of treatment, cleaved PARP appeared in all 14 cases. Time-course analysis of cell cycle progression and apoptosis showed that PD98059 induced a G1-phase accumulation with low or undetectable levels of apoptosis after 24 h incubation; after 48 and 72 h incubation, a significant increase of apoptosis was observed. Thus, the primary effect of ERK downmodulation was a cell cycle arrest followed by the apoptosis of a significant percentage of the leukemic blasts. The preclinical model of leukemia treatment reported in this paper makes further comment with regard to MEK1 inhibition as a useful antileukemic target, and encourages the conducting of in vivo studies and clinical investigations.
Collapse
Affiliation(s)
- P Lunghi
- Department of Clinical Sciences, Section of Hemato-Oncology, University of Parma Medical School, Parma, Italy
| | | | | | | | | | | | | |
Collapse
|
42
|
Lunghi P, Tabilio A, Pinelli S, Valmadre G, Ridolo E, Albertini R, Carlo-Stella C, Dall'Aglio PP, Pelicci PG, Bonati A. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. Hematol J 2001; 2:70-80. [PMID: 11423998 DOI: 10.1038/sj/thj/6200095] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/13/2000] [Accepted: 12/29/2000] [Indexed: 04/16/2023]
Abstract
INTRODUCTION We report the results of a study investigating signaling proteins in 26 cases of primary acute myelogenous leukemia. We studied the Shc adaptor proteins p52/p46Shc, which can activate the RAS/Mitogen Activated Protein kinase pathway, p66Shc which is uncoupled from RAS/MAP kinases and the MAP kinase family members Extracellular signal Regulated Kinase (ERK) and c-Jun NH2-terminal protein Kinase (JNK) or Stress Activated Protein Kinase (SAPK). MATERIAL AND METHODS CD34+ and CD34- fractions of four human normal bone marrow and unfractionated bone marrow samples were investigated. Immunoblottings, immunoenzymatic and in vitro assays were performed. RESULTS Shc protein isoforms were constitutively expressed in all the AML cases examined. Tyrosine-phosphorylation of p53/p46Shc isoforms were found in CD34+ but not in the majority of CD34- cases. p66Shc isoform was not tyrosine-phosphorylated in CD34-, and was tyrosine-phosphorylated only in some CD34+ cases. Expression and activation of ERK was constitutively present in the majority of AML patients analysed. JNK/SAPK was expressed but not activated in the AMLs examined. Activation occurred after treatment of the leukemic cells by anisomycin, etoposide, and cytarabine. ERK and JNK/SAPK activation were not detectable in the hematopoietic precursors of human normal bone-marrow. CONCLUSION These data bear implications for the role of Shc-MAP kinase pathway in normal hemopoiesis and AML leukemogenesis.
Collapse
Affiliation(s)
- P Lunghi
- The Institute of Medical Pathology, University of Parma Medical School, Parma, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Cilloni D, Carlo-Stella C, Falzetti F, Sammarelli G, Regazzi E, Colla S, Rizzoli V, Aversa F, Martelli MF, Tabilio A. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 2000; 96:3637-43. [PMID: 11071665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
The engraftment capacity of bone marrow-derived mesenchymal cells was investigated in 41 patients who had received a sex-mismatched, T-cell-depleted allograft from human leukocyte antigen (HLA)-matched or -mismatched family donors. Polymerase chain reaction (PCR) analysis of the human androgen receptor (HUMARA) or the amelogenin genes was used to detect donor-derived mesenchymal cells. Only 14 marrow samples (34%) from 41 consenting patients generated a marrow stromal layer adequate for PCR analysis. Monocyte-macrophage contamination of marrow stromal layers was reduced below the levels of sensitivity of HUMARA and amelogenin assays (5% and 3%, respectively) by repeated trypsinizations and treatment with the leucyl-leucine (leu-leu) methyl ester. Patients who received allografts from 12 female donors were analyzed by means of the HUMARA assay, and in 5 of 12 cases a partial female origin of stromal cells was demonstrated. Two patients who received allografts from male donors were analyzed by amplifying the amelogenin gene, and in both cases a partial male origin of stromal cells was shown. Fluorescent in situ hybridization analysis using a Y probe confirmed the results of PCR analysis and demonstrated in 2 cases the existence of a mixed chimerism at the stromal cell level. There was no statistical difference detected between the dose of fibroblast progenitors (colony-forming unit-F [CFU-F]) infused to patients with donor- or host-derived stromal cells (1.18 +/- 0.13 x 10(4)/kg vs 1. 19 +/- 0.19 x 10(4)/kg; P >/=.97). In conclusion, marrow stromal progenitors reinfused in patients receiving a T-cell-depleted allograft have a limited capacity of reconstituting marrow mesenchymal cells.
Collapse
Affiliation(s)
- D Cilloni
- Department of Hematology, University of Parma, Parma, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Di Nicola M, Carlo-Stella C, Milanesi M, Magni M, Longoni P, Mortarini R, Anichini A, Tomanin R, Scarpa M, Gianni AM. Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. Br J Haematol 2000; 111:344-50. [PMID: 11091223 DOI: 10.1046/j.1365-2141.2000.02258.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
With a view to using multiple injections of anti-cancer dendritic cell (DC)-based vaccines, we evaluated the feasibility of the adenoviral transduction of large amounts of human CD34+ cell-derived DCs, and analysed the persistence of the transgene expression and the integrity of DC functional activity after the transduction/cryopreservation procedures. Mature DCs generated from highly enriched human CD34+ cells were transduced by a recombinant adenovirus (rAd-MFG) that carried a modified, membrane-exposed, alkaline phosphatase (AP) sequence as the reporter gene. Cationic lipids such as LipofectAmine or poly-L-lysine were mixed with the viral particles before the transduction of the target cells. The highest transduction efficiency was obtained at a multiplicity of infection (MOI) rate of 500 (AP + DCs: 50 +/- 2%, viability =95%) under both small- and large-scale conditions. The addition of poly-L-lysine or LipofectAmine increased the percentage of transduced cells at an MOI of 500 (CD1a+/AP+ cells = 85 +/- 3% and 80 +/- 2% respectively). Polycations made it possible to reduce the amounts of viral particles, with high efficiency of transduction being achieved at a MOI of 100 with 10 microg/ml poly-L-lysine (CD1a+/AP+: 68 +/- 9%) or 30 microg/ml LipofectAmine (CD1a+/AP+: 60 +/- 7%). Evaluation of the immunophenotype of the transduced DCs showed that the lack of a DC subpopulation was more susceptible to adenoviral transduction. Cryopreservation of transduced DCs did not modify the viability or percentage of AP+ cells that maintain antigen-presenting cell (APC) functions. These findings indicate the efficacy of this method for the transduction of large amounts of CD34+ cell-derived DCs using small quantities of adenoviral vector mixed with polycations. Cryopreservation of transduced DCs did not damage their viability or APC functions, thus making it possible to plan multiple injections of engineered DC-based vaccines.
Collapse
Affiliation(s)
- M Di Nicola
- Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Buschini A, Anceschi E, Carlo-Stella C, Regazzi E, Rizzoli V, Poli P, Rossi C. Amifostine (WR-2721) selective protection against melphalan genotoxicity. Leukemia 2000; 14:1642-51. [PMID: 10995012 DOI: 10.1038/sj.leu.2401877] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Amifostine (WR-2721) is an aminothiol compound dephosphorylated at the tissue site by alkaline phosphatase to the active metabolite, which is able to inactivate electrophilic substances and scavenge free radicals. Amifostine effects against melphalan-induced DNA strand breaks were studied in normal human white blood cells (WBC) and K562 leukemic cells using the single cell gel electrophoresis (SCGE) or Comet assay, a reported method for measuring DNA damage in individual cells. Prior to treatment (1 h, 37 degrees C) with increasing doses of melphalan, with or without S9, the cells were treated (15 min, 37 degrees C) with a control medium or amifostine (3 mg/ml). Treatment of normal and leukemic cells with melphalan induced a dose-dependent 'comet formation'. Melphalan-induced DNA damage follows a normal distribution in WBC. On the other hand, in K562, a significant proportion of undamaged cells remains even with doses at which mean DNA damage is serious. Pretreatment with WR-2721 protects WBC, but not K562, against the genotoxic effect of melphalan. Amifostine might even strengthen the action of the antiblastic drug against K562 cells. S9 addition appears to enhance melphalan effectiveness. SCGE appears as a suitable primary screening method for in vitro and in vivo studies on drug-DNA interactions and their modulations by endogenous/exogenous factors.
Collapse
Affiliation(s)
- A Buschini
- Istituto di Genetica, Università di Parma, Italy
| | | | | | | | | | | | | |
Collapse
|
46
|
Fogli M, Carlo-Stella C, Curti A, Ratta M, Tazzari PL, Ragazzi E, Colla S, Santucci AM, Tura S, Lemoli RM. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. Exp Hematol 2000; 28:775-83. [PMID: 10907639 DOI: 10.1016/s0301-472x(00)00173-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Transforming growth factor beta3 (TGF-beta3) is a potent suppressor of human hematopoietic progenitor cells. In this article, we compare the activity of TGF-beta3 on highly purified CD34+ cells and more immature CD34-DR(-) cells from chronic myelogenous leukemia (CML) patients in chronic phase and normal donors. MATERIALS AND METHODS Primitive hematopoietic progenitors were stimulated in liquid cultures and clonogenic assays by early-acting growth factors such as stem cell factor (SCF) and interleukin 11 (IL-11) and the intermediate-late-acting stimulating factors IL-3, granulocyte-macrophage colony-stimulating factor, and erythropoietin. Molecular analysis of bcr/abl mRNA was performed on single CML colonies by nested reverse transcriptase polymerase chain reaction. Moreover, cell cycle analysis and assessment of apoptosis of normal and leukemic CD34+ cells were performed by propidium iodide (PI) alone and simultaneous staining with annexin V and PI, respectively. RESULTS The colony-forming efficiency of CML CD34+ cells was generally inhibited by more than 90% regardless of whether the colony-stimulating factors were used alone or combined. When compared to normal CD34+ cells, leukemic cells were significantly more suppressed in 6 of 8 culture conditions. The inhibitory effect of TGF-beta3 on CD34+ cells was exerted within the first 24 hours of incubation as demonstrated by short-term preincubation followed by IL-3-and SCF-stimulated colony assays. Evaluation of bcr/abl transcript on residual CML colonies incubated with TGF-beta3 demonstrated a small subset of neoplastic CD34+ cells unresponsive to the inhibitory effect of the study cytokine. TGF-beta3 demonstrated a greater inhibitory activity on primitive CD34+DR cells than on more mature CD34+ cells. Again, CML CD34+DR(-) cells were significantly more inhibited by TGF-beta3 than their normal counterparts in 3 of 8 culture conditions. Kinetic analysis performed on CD34+ cells showed that TGF-beta induces cell cycle arrest in G(1) phase. However, this mechanism of action is shared by normal and leukemic cells. Conversely, TGF-beta3 preferentially triggered the programmed cell death of CML CD34-cells without increasing the proportion of leukemic cells coexpressing CD95 (Fas receptor), and this effect was not reversed by functional blockade of Fas receptor. Conclusion. We demonstrate that TGF-beta3 exerts a potent suppressive effect on CML cells that is partly mediated by Fas-independent apoptosis.
Collapse
Affiliation(s)
- M Fogli
- Institute of Hematology and Medical Oncology L. & A. Seràgnoli, University of Bologna, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
PURPOSE To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation. MATERIALS AND METHODS A search of MEDLINE was conducted to identify relevant publications. Their bibliographies were also used to identify further articles and abstracts for critical review. RESULTS The CD34(+) cell content of a graft is regarded as an accurate predictor of engraftment success. Postchemotherapy autologous PBPC transplantation with >/= 5 x 10(6) CD34(+) cells/kg body weight leads to more rapid engraftment than does transplantation of lower cell doses. Further increases in transplant cell dose further accelerate platelet but not neutrophil engraftment. Evidence that long-term hematopoietic recovery may be more accurately predicted by the subpopulation of primitive progenitors transplanted suggests that the content of CD34(+)CD33(-) and long-term culture-initiating cells in cell collection samples may be important for predicting successful engraftment, particularly in patients with poor mobilization. Allogeneic transplantation has been limited by concerns regarding graft-versus-host disease and the use of hematopoietic growth factors in donors. The risk of graft rejection and engraftment failure after HLA-mismatched allogeneic transplantation may be overcome by intensive chemoradiotherapy and the infusion of large numbers of T cell-depleted hematopoietic stem cells. CONCLUSION An optimal cell dose of >/= 8 x 10(6) CD34(+) cells/kg seems to be recommended for autologous PBPC transplantation. This dose facilitates the administration of scheduled chemotherapy on time and reduces the demand for other supportive therapies. A combination of growth factors may enable patients with poor mobilization to achieve a collection sufficient to allow transplantation. The optimum PBPC dose for allogeneic transplantation remains to be defined.
Collapse
Affiliation(s)
- S Siena
- Falck Division of Medical Oncology, Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.
| | | | | | | |
Collapse
|
48
|
Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, Sammarelli G, Savoldo B, Tabilio A, Dall'Aglio PP, Pelicci PG. Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias. Cancer Res 2000; 60:728-32. [PMID: 10676660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The BCR/ABL fusion protein is a constitutively active tyrosine kinase that is responsible for the pathogenesis of chronic myelogenous leukemia (CML). Clinically, CML is characterized by a chronic phase (CP) that eventually terminates into a blast crisis (BC). BC transformation is associated with accumulation of CD34+ blasts. We investigated the expression and phosphorylation of Src-homology-2 and collagen-homology domains (SHC) [corrected] proteins in subpopulations of CML primary cells. Shc polypeptides are tyrosine kinase substrates that are constitutively tyrosine-phosphorylated in continuous cell lines of CML origin. High levels of Shc expression were found in the CD34+ cells from CML-BC, CML-CP and normal bone marrow. In contrast, CD34- fractions from CML-CP and normal bone marrow expressed low levels of p46Shc. Shc proteins were constitutively phosphorylated in the CD34+ fractions from CML cells (both CP and BC), but not in normal CD34+ cells. These data bear implications for the role of Shc in normal hemopoiesis and CML leukemogenesis: (a) dramatic changes of Shc expression during terminal differentiation of hemopoietic cells adds a further level of regulation to the signal transduction function of Shc; and (b) constitutive Shc tyrosine-phosphorylation in the rare CD34+ cells of CML-CP might contribute to the selection of this subpopulation during the blast crisis transformation of CMLs.
Collapse
Affiliation(s)
- A Bonati
- The Institute of Medical Pathology, University of Parma, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Carlo-Stella C, Cesana C, Regazzi E, Falzetti F, Aversa F, Rizzoli V, Martelli M, Tabilio A. Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor. Exp Hematol 2000; 28:216-24. [PMID: 10706078 DOI: 10.1016/s0301-472x(99)00139-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE We analyzed the incidence of primitive (LTC-IC) and committed (CFU-mix, BFU-E, CFU-GM) hematopoietic progenitors detected under steady-state conditions and upon progenitor cell mobilization in a cohort of healthy donors receiving recombinant human granulocyte colony-stimulating factor (rhG-CSF). MATERIALS AND METHODS Healthy donors (n = 30) of HLA-mismatched or -matched stem cell transplants were mobilized with rhG-CSF (8 microg/Kg body weight subcutaneously twice daily until completion of leukapheresis). PBPC collections were started after 4 days of rhG-CSF therapy. RESULTS Steady-state incidence of bone marrow LTC-IC, but not committed progenitors, significantly correlated with the numbers of mobilized CD34+ cells (r = 0.6, p = 0.004), CFU-GM (r = 0.79, p = 0.0005) and CFC (r = 0.76, p = 0.001) detected after 4 days of rhG-CSF therapy. Statistically significant correlations were also found between steady-state blood CFU-GM and peak numbers of CD341 cells (r = 0.68, p = 0.001), numbers of day 4 CD341 cells (r = 0.52, p = 0.005), CFU-GM (r = 0.63, p = 0.002), and CFC (r = 0.61, p = 0.003). CONCLUSION Our data show that in normal volunteers baseline marrow LTC-IC and blood CFU-GM correlate with rhG-CSF-mobilized PBPC. The potential clinical relevance of these findings in the identification of poor mobilizers will be tested in a prospective study.
Collapse
|
50
|
Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P, Tura S. Cell therapy: achievements and perspectives. Haematologica 1999; 84:1110-49. [PMID: 10586214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Cell therapy can be considered as a strategy aimed at replacing, repairing, or enhancing the biological function of a damaged tissue or system by means of autologous or allogeneic cells. There have been major advances in this field in the last few years. This has prompted the Working Group on Hematopoietic Cells to examine the current utilization of this therapy in clinical hematology. EVIDENCE AND INFORMATION SOURCES The method employed for preparing this review was that of informal consensus development. Members of the Working Group met three times, and the participants at these meetings examined a list of problems previously prepared by the chairman. They discussed the single points in order to reach an agreement on different opinions and eventually approved the final manuscript. Some of the authors of the present review have been working in the field of cell therapy and have contributed original papers in peer-reviewed journals. In addition, the material examined in the present review includes articles and abstracts published in journals covered by the Science Citation Index and Medline. STATE OF THE ART Lymphokine-activated killer (LAK) and tumor-infiltrating lymphocytes (TIL) have been used since the '70s mainly in end-stage patients with solid tumors, but the clinical benefits of these treatments has not been clearly documented. TIL are more specific and potent cytotoxic effectors than LAK, but only in few patients (mainly in those with solid tumors such as melanoma and glioblastoma) can their clinical use be considered potentially useful. Adoptive immunotherapy with donor lymphocyte infusions has proved to be effective, particularly in patients with chronic myeloid leukemia, in restoring a state of hematologic remission after leukemia relapse occurring following an allograft. The infusion of donor T-cells can also have a role in the treatment of patients with Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative disorders. However, in this regard, generation and infusion of donor-derived, virus specific T-cell lines or clones represents a more sophisticated and safer approach for treatment of viral complications occurring in immunocompromised patients. Whereas too few clinical trials have been performed so far to draw any firm conclusion, based on animal studies dendritic cell-based immunotherapy holds promises of exerting an effective anti-tumor activity. Despite leukemic cells not being immunogenic, induction on their surface of co-stimulatory molecules or generation of leukemic dendritic cells may induce antileukemic cytotoxic T-cell responses. Tumor cells express a variety of antigens and can be genetically manipulated to become immunogenic. The main in vitro and in vivo functional characteristics of marrow mesenchymal stem cells (MSCs) with particular emphasis on their hematopoietic regulatory role are reviewed. In addition, prerequisites for clinical applications using culture-expanded mesenchymal cells are discussed PERSPECTIVES The opportuneness of using LAK cells or activated natural killer (NK) cells in hematologic patients with low tumor burden (e.g. after stem cell transplantation) should be further explored. Moreover the role of new cytokines in enhancing the antineoplastic activity of NK cells and the infusion of selected NK in alternative to CTL for graft versus leukemia (GVL) disease (avoiding graft versus host disease (GvHD) seems very promising. Separation of GVL from GvHD through generation and infusion of leukemia-specific T-cell clones or lines is one of the most intriguing and promising fields of investigations for the future. Likewise, strategies devised to improve immune-reconstitution and restore specific anti-infectious functions through either induction of unresponsiveness to recipient alloantigens or removal of alloreactive donor T-cells might increase the applicability and success of hematopoietic stem cell transplantation. (ABSTRACT TRUNCATED)
Collapse
Affiliation(s)
- C Bordignon
- Institute of Hematology, S. Raffaele Hospital, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|